| Primary |
| Bronchiectasis |
25.1% |
| Cystic Fibrosis |
10.5% |
| Cystic Fibrosis Lung |
8.1% |
| Chronic Obstructive Pulmonary Disease |
7.3% |
| Medical Diet |
6.5% |
| Gastrooesophageal Reflux Disease |
5.3% |
| Pancreatic Insufficiency |
5.3% |
| Asthma |
4.9% |
| Hypertension |
4.0% |
| Prophylaxis |
4.0% |
| Pneumonia |
2.8% |
| Rhinitis Allergic |
2.8% |
| Dyspnoea |
2.4% |
| Constipation |
1.6% |
| Hypersensitivity |
1.6% |
| Insomnia |
1.6% |
| Lung Disorder |
1.6% |
| Osteopenia |
1.6% |
| Urinary Tract Infection |
1.6% |
| Attention Deficit/hyperactivity Disorder |
1.2% |
|
| Bronchiectasis |
15.7% |
| Haemoptysis |
9.8% |
| Rash |
9.8% |
| Asthma |
7.8% |
| Lung Disorder |
7.8% |
| Pneumothorax |
7.8% |
| Anaphylactic Reaction |
5.9% |
| Drug Hypersensitivity |
5.9% |
| Hypersensitivity |
3.9% |
| Rash Maculo-papular |
3.9% |
| White Blood Cell Count Decreased |
3.9% |
| Coma |
2.0% |
| Cough |
2.0% |
| Diplopia |
2.0% |
| Disease Progression |
2.0% |
| Dizziness |
2.0% |
| Drug Eruption |
2.0% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
2.0% |
| Dyspnoea |
2.0% |
| Liver Function Test Abnormal |
2.0% |
|
| Secondary |
| Cystic Fibrosis |
10.6% |
| Bronchiectasis |
10.1% |
| Infection |
8.6% |
| Drug Use For Unknown Indication |
8.1% |
| Product Used For Unknown Indication |
8.1% |
| Acute Myeloid Leukaemia |
6.1% |
| Pyrexia |
6.1% |
| Ill-defined Disorder |
5.1% |
| Asthma |
4.5% |
| Cellulitis |
4.5% |
| Chronic Obstructive Pulmonary Disease |
4.5% |
| Anxiety |
4.0% |
| Bacterial Infection |
3.0% |
| Medical Diet |
3.0% |
| Convulsion |
2.5% |
| Epstein-barr Virus Infection |
2.5% |
| Pancreatic Insufficiency |
2.5% |
| Aneurysm Ruptured |
2.0% |
| Anti-infective Therapy |
2.0% |
| Anxiety Disorder |
2.0% |
|
| Toxic Epidermal Necrolysis |
20.0% |
| Drug Hypersensitivity |
14.3% |
| Tubulointerstitial Nephritis |
8.6% |
| Infection |
5.7% |
| Nausea |
5.7% |
| Renal Failure Acute |
5.7% |
| Base Excess Decreased |
2.9% |
| Bronchiectasis |
2.9% |
| Caesarean Section |
2.9% |
| Convulsion |
2.9% |
| Cytolytic Hepatitis |
2.9% |
| Depression |
2.9% |
| Drug Eruption |
2.9% |
| Drug Ineffective |
2.9% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
2.9% |
| Drug Withdrawal Syndrome |
2.9% |
| Faecal Incontinence |
2.9% |
| Haemoptysis |
2.9% |
| Neutropenia |
2.9% |
| Premature Delivery |
2.9% |
|
| Concomitant |
| Product Used For Unknown Indication |
38.8% |
| Drug Use For Unknown Indication |
14.8% |
| Prophylaxis |
8.2% |
| Adverse Event |
5.3% |
| Aplastic Anaemia |
4.2% |
| Pain |
3.6% |
| Acute Myeloid Leukaemia |
3.3% |
| Multiple Myeloma |
2.9% |
| Cystic Fibrosis |
2.0% |
| Insomnia |
2.0% |
| Infection Prophylaxis |
1.9% |
| Sepsis |
1.9% |
| Hypertension |
1.7% |
| Prophylaxis Against Gastrointestinal Ulcer |
1.6% |
| Pneumonia |
1.4% |
| Nausea |
1.3% |
| Anaemia |
1.3% |
| Constipation |
1.3% |
| Hypophagia |
1.3% |
| Pseudomonas Infection |
1.2% |
|
| Wound Secretion |
10.9% |
| Urinary Tract Infection |
10.2% |
| Respiratory Failure |
8.6% |
| White Blood Cell Count Decreased |
7.0% |
| Sepsis |
6.3% |
| Infective Pulmonary Exacerbation Of Cystic Fibrosis |
5.5% |
| Renal Failure |
5.5% |
| Pneumonia |
4.7% |
| Thrombocytopenia |
4.7% |
| Toxic Epidermal Necrolysis |
4.7% |
| Hepatic Failure |
3.9% |
| Septic Shock |
3.9% |
| Hypoglycaemia |
3.1% |
| Hypotensive Transfusion Reaction |
3.1% |
| International Normalised Ratio Increased |
3.1% |
| Stenotrophomonas Infection |
3.1% |
| Urosepsis |
3.1% |
| Visual Field Defect |
3.1% |
| Vomiting |
3.1% |
| Cardiomyopathy |
2.3% |
|
| Interacting |
|
|
